A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation

Table 1

Demographics and baseline characteristics of subjects.

Time of conversion after transplant	Early	Late	Total
Number of subjects	187	297	484
Number of subjects by region
(i) North America	55	84	139
(ii) South America	129	207	336
(iii) Europe	2	4	6
(iv) Other	1	2	3
Mean age (years)^*	45 ± 14	35 ± 15	39 ± 15
Gender (male)	120 (64%)	178 (60%)	298 (62%)
Ethnicity^*
(i) Caucasian	141 (75%)	212 (71%)	353 (73%)
(ii) Black	31 (17%)	29 (10%)	60 (12%)
(iii) Hispanic	12 (6%)	46 (16%)	58 (12%)
(iv) Asian	1 (1%)	3 (1%)	4 (1%)
(v) Other	2 (1%)	7 (2%)	9 (2%)
Primary kidney disease
(i) Glomerulonephritis	50 (27%)	102 (34%)	152 (31%)
(ii) Diabetes mellitus	17 (9%)	17 (6%)	34 (7%)
(iii) Hypertension	31 (17%)	42 (14%)	73 (15%)
(iv) Polycystic kidney disease	10 (5%)	25 (8%)	35 (7%)
Transplant number
(i) First transplant	167 (89%)	273 (92%)	440 (91%)
(ii) Retransplant	20 (11%)	24 (8%)	44 (9%)
Donor source^*
(i) Deceased donor	135 (72%)	132 (44%)	267 (55%)
(ii) Living donor	48 (26%)	162 (55%)	210 (43%)
(iii) Not reported	4 (2%)	3 (1%)	7 (2%)
Panel reactive antibodies (%)	8 ± 20	6 ± 16	7 ± 18
Time to start of sirolimus (months)	3 ± 3	61 ± 38	39 ± 41
Posttransplant followup (months)	27 ± 14	24 ± 12	25 ± 13
Reason for commencing sirolimus
(i) Deteriorating graft function	38 (20.3%)	108 (36.4%)	146 (30.2%)
(ii) Adverse effects of prior immunosuppressants	55 (29.4%)	89 (30.0%)	144 (29.8%)
(iii) Routine practice within centre	26 (13.9%)	14 (4.7%)	40 (8.3%)
(iv) Delayed graft function	29 (15.5%)	2 (0.7%)	31 (6.4%)
(v) Rejection on prior immunosuppression	5 (2.7%)	9 (3.0%)	14 (2.9%)
(vi) Contraindications to an other immunosuppression	4 (2.1%)	1 (0.3%)	5 (1.0%)
(vii) Other	30 (16.0%)	74 (24.9%)	104 (21.5%)

^∗𝑃<0.05.